MannKind Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind or view top-rated stocks.

Wall Street analysts have given MannKind a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MannKind wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for MannKind.

MannKind Co. (NASDAQ:MNKD) announced its quarterly earnings data on Wednesday, May, 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.
View MannKind's earnings history.

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD stock has increased by 268.2% and is now trading at $4.05.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1-year target prices for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's share price to reach $6.30 in the next twelve months. This suggests a possible upside of 55.6% from the stock's current price.
View analysts' price targets for MannKind or view top-rated stocks among Wall Street analysts.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of MNKD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.53%), Geode Capital Management LLC (1.54%), Millennium Management LLC (1.16%), Northern Trust Corp (0.97%), Eversept Partners LP (0.87%) and Nuveen Asset Management LLC (0.79%). Company insiders that own MannKind stock include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind.

MNKD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, EAM Global Investors LLC, EAM Investors LLC, Credit Suisse AG, Northern Trust Corp, Squarepoint Ops LLC, Alliancebernstein L.P., and Cambridge Investment Research Advisors Inc..
View insider buying and selling activity for MannKind or view top insider-selling stocks.

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Eversept Partners LP, Schonfeld Strategic Advisors LLC, Citigroup Inc., Millennium Management LLC, BlackRock Inc., Rafferty Asset Management LLC, Nuveen Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind or or view top insider-buying stocks.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MNKD stock can currently be purchased for approximately $4.05.

MannKind has a market capitalization of $1.01 billion and generates $65.14 million in revenue each year. The biopharmaceutical company earns $-57,240,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

MannKind employs 240 workers across the globe.

MannKind was founded in 1991.

The official website for MannKind is www.mannkindcorp.com.

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]